IDEXX Laboratories stock gains as analysts lift targets

Published on 09/11/2026 at 14:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEXX Laboratories stock drew a 722.23 USD average target on September 11, 2026. Q2 revenue rose 9.7 percent and comparable EPS increased 15.3 percent.

Moderne Veterinärdiagnostik-Labor mit Analysegeräten, Blutproben und Technikerin — IDEXX Laboratories US45168D1046 zeigt ein modernes Veterinärdiagnostik Labor mit Analysegeräten und Technikerin, Illustration mit AI erstellt.

IDEXX Laboratories stock (ISIN US45168D1046) is trading near USD 506.53, with a market capitalization of USD 39.91 billion on September 11, 2026. On the same day, 15 analysts averaged a 722.23 USD target, according to ET Net.

Q2 numbers set the tone

ET Net said on September 11, 2026 that IDEXX Laboratories' second quarter revenue rose 9.7 percent year over year and comparable EPS increased 15.3 percent. The same report said the company lifted its 2026 full-year revenue and earnings guidance.

Stock still trails target

At USD 506.53, the shares sat far below the 722.23 USD average target cited for September 11, 2026, leaving a gap of about 42.5 percent. Benzinga also noted on September 10, 2026 that insider activity included an options exercise by Lawrence D. Kingsley valued at USD 873,000.

Market level

For investors, the key level is still the USD 506.53 quote on September 11, 2026, alongside the USD 514.30 intraday high and USD 504.91 low in the same session. Market capitalization stood at USD 39.91 billion on September 11, 2026.